Previous 10 | Next 10 |
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here . NanoViricides (NYSE American: NNVC) has begun trials for its new drug candidate, NV-CoV-2 — an exciting development for the biotech company, as it starts its first human tr...
SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its broad-spectrum antiviral clinica...
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here . NanoViricides (NYSE American: NNVC) is a drug development company working on a novel nanomedical treatment. It recently updated the world on the status of its long-awaited and now...
SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily. NanoViricides is a clinical-stage global leader in the development of highly effectiv...
--News Direct-- NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share news about the beginning of clinical trials for its broad-spectrum antiviral drug NV-CoV-2. This is with two oral drug products NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies. Diwan told Proac...
SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. "We bel...
2023-06-01 13:29:35 ET Gainers: U Power Limited UCAR +197% . Wearable Devices ( WLDS ) +36% . Lands' End LE +35% . QuantaSing Group Limited QSG +31% . D-Wave Quantum ( QBTS ) +25% . Chewy CHWY +25% . Vision Marine Technologies ( ...
SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET. In addition to the conferen...
SHELTON, CT / ACCESSWIRE / May 16, 2023 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission (SEC) on Monday, May 15, 2023. The report c...
2023-05-05 18:33:14 ET Nanoviricides ( NYSE: NNVC ) has filed for a $150M mixed shelf securities offering. The company indicated it plans to use the proceeds for general corporate purposes. The offering can include common stock, preferred stock, debt securities, warran...
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory viral infe...
SHELTON, CT / ACCESSWIRE / July 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutioni...
--News Direct-- NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share promising news about the company's ultra-broad-spectrum antiviral, NV-387. The antiviral was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse mod...